Splice Bio closed a $135 million Series B funding round to support its gene therapy pipeline aimed at treating rare genetic diseases. Leadership discussed strategic fundraising amid a challenging investment landscape, highlighting the critical importance of sustained capital to advance preclinical and clinical programs. The capital injection underscores investor confidence in gene therapy's potential despite broader financial headwinds impacting biotech startups.